主页 > 医学前沿 >
【drug-news】有机砷治疗肿瘤?
At Ziopharm, Arsenic Is Not So Toxic
Arsenic to treat cancer? So advocates Dr. Jonathan Lewis, professor of surgery and medicine at Memorial Sloan-Kettering Cancer Center from 1994 to 2001 and now CEO of Ziopharm Oncology (ZIOP ). Arsenic has long been in medical use, he says, and there's renewed interest since the approval of Cephalon's inorganic-arsenic drug Trisenox in 2000. Extremely effective against rare hematological cancers, Trisenox' wider use is hampered by its toxicity, says Lewis. (It carries a Food & Drug Administration warning as potentially lethal.) But the arsenic that Ziopharm uses in its Darinaparsin (ZIO-101) is organic, which reduces most toxic side effects, Lewis says. "We are testing its use in treating myeloma and other blood cancers." ZIO-101 and another drug aimed at sarcoma, ZIO-201, are both in Phase 2 clinical trials. "ZIO-101 is the first of a new class of arsenicals that are potentially safer and more effective for cancer treatment," says Chrystyna Bedrij of Griffin Securities, who rates the stock, now at 4.90, a buy, with a year's target of 20. On July 9, Ziopharm announced "positive interim data" from the ZIO-201 trials. Vinny Jindal of ThinkEquity Partners, also with a buy, notes that an oral form of ZIO-101 got FDA approval for human clinical testing. 认领！ At Ziopharm, Arsenic Is Not So Toxic 砷没有那么大的毒性
Arsenic to treat cancer? So advocates Dr. Jonathan Lewis, professor of surgery and medicine at Memorial Sloan-Kettering Cancer Center from 1994 to 2001 and now CEO of Ziopharm Oncology (ZIOP ).
用砷来治疗癌症？提倡者- Jonathan Lewis博士，是1994年到2001年Memorial Sloan-Kettering癌症中心外科教授，现在是Ziopharm肿瘤学的最高负责人。
Arsenic has long been in medical use, he says, and there's renewed interest since the approval of Cephalon's inorganic-arsenic drug Trisenox in 2000.
他说，砷用于医学已经很长时间了，自从无机砷类药-三氧二砷问世以来人们又有了新的兴趣。
Extremely effective against rare hematological cancers, Trisenox' wider use is hampered by its toxicity, says Lewis. (It carries a Food & Drug Administration warning as potentially lethal.)
Lewis说三氧二砷是对罕见血癌非常有效的药物，它的毒性使其不能被广泛使用（食物和药物管理局说它有潜在的致死性）。
But the arsenic that Ziopharm uses in its Darinaparsin (ZIO-101) is organic, which reduces most toxic side effects, Lewis says. "We are testing its use in treating myeloma and other blood cancers."
但是Ziopharm在Darinaparsin (ZIO-101)中用的是有机体砷，它可减少大部分的毒性副作用。Lewis说“我们正在检测其对骨髓瘤和其它血癌的治疗”。
ZIO-101 and another drug aimed at sarcoma, ZIO-201, are both in Phase 2 clinical trials. ZIO-101和另一种药物ZIO-201主要是用于肉瘤，它们都处于临床试验的第2相。
"ZIO-101 is the first of a new class of arsenicals that are potentially safer and more effective for cancer treatment," says Chrystyna Bedrij of Griffin Securities, who rates the stock, now at 4.90, a buy, with a year's target of 20.
监督安全局的Chrystyna Bedrij说，ZIO-101是癌症治疗较安全和有效的新一代砷类药物中第一个研究的，他说现在购买要4.90，一年后将是20。
On July 9, Ziopharm announced "positive interim data" from the ZIO-201 trials. Vinny Jindal of ThinkEquity Partners, also with a buy, notes that an oral form of ZIO-101 got FDA approval for human clinical testing.在7月9日，Ziopharm宣布ZIO-201试验有了阳性结果。ThinkEquity的搭档，Vinny Jindal也同意说ZIO-101的口服药物用于人临床试验得到了食品和药物管理局的赞同。 整理如下：
砷没有那么大的毒性
用砷来治疗癌症？提倡者- Jonathan Lewis博士，是1994年到2001年Memorial Sloan-Kettering癌症中心外科教授，现在是Ziopharm肿瘤学的最高负责人。他说，砷用于医学已经很长时间了，自从无机砷类药-三氧二砷问世以来人们又有了新的兴趣。Lewis说三氧二砷是对罕见血癌非常有效的药物，它的毒性使其不能被广泛使用（食物和药物管理局说它有潜在的致死性）。但是Ziopharm在Darinaparsin (ZIO-101)中用的是有机体砷，它可减少大部分的毒性副作用。Lewis说“我们正在检测其对骨髓瘤和其它血癌的治疗”。ZIO-101和另一种药物ZIO-201主要是用于肉瘤，它们都处于临床试验的第2相。监督安全局的Chrystyna Bedrij说，ZIO-101是癌症治疗较安全和有效的新一代砷类药物中第一个研究的，他说现在购买要4.90，一年后将是20。在7月9日，Ziopharm宣布ZIO-201试验有了阳性结果。ThinkEquity的搭档，Vinny Jindal也同意说ZIO-101的口服药物用于人临床试验得到了食品和药物管理局的赞同。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-30 19:24
医学,生命科学网